Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Timothy Price, Subotheni Thavaneswaran, Matthew Burge, Eva Segelov, Daniel Haller, Cornelis Punt, Dirk Arnold, Christos Karapetis, Niall Tebbutt, Nick Pavlakis, Peter Gibbs, Jeremy Shapiro

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    ABSTRACT: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.

    Original languageEnglish
    Pages (from-to)557-571
    Number of pages15
    JournalExpert Review of Anticancer Therapy
    Volume16
    Issue number5
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015'. Together they form a unique fingerprint.

  • Cite this

    Price, T., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D., Punt, C., Arnold, D., Karapetis, C., Tebbutt, N., Pavlakis, N., Gibbs, P., & Shapiro, J. (2016). Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16(5), 557-571. https://doi.org/10.1586/14737140.2016.1170594